Protective effects of ME3221 on hypertensive complications lifespan in salt-loaded stroke-prone spontaneously hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 3, 1996, Pages 229-235

  Nagura, Jun ^a   Yamamoto, Mikio ^a   Hui, Chen ^a   Yasuda, Sumie ^a   Hachisu, Mitsugu ^a   Konno, Fukio ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

Angiotensin AT1; Hypertensive complications; Losartan; ME3221; Receptor antagonist; Stroke prone spontaneously hypertensive rats

Indexed keywords

3 METHOXY 2,6 DIMETHYL 4 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHOXY]PYRIDINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ENALAPRIL; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SALT INTAKE; STROKE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; BODY WEIGHT; CEREBRAL HEMORRHAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; HYPERTENSION; IMIDAZOLES; LOSARTAN; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0029897445     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb02601.x     Document Type: Article

References (33)

1. Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ. Res. 1974; 34-35 (Suppl. 1): 143-53.
2. Nagaoka A, Iwatsuka H, Suzuki Z, Okamoto K. Genetic predisposition to stroke in spontaneously hypertensive rats. Am. J. Physiol. 1976; 230: 1354-9.
3. Stier CT Jr, Benter IF, Ahmad S et al. Enalapril prevents stroke-prone spontaneously hypertensive rats. Hypertension 1989; 13: 115-21.
4. Stier CT Jr, Chander P, Gutstein WH, Levine S, Itskovitz HD. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am. J. Hyp. 1991; 4: 680-7.
5. Stier CT Jr, Sim G, Mahboubi K, Shen W, Levine S, Chander PN. Prevention of stroke and hypertensive renal disease by the angiotensin II receptor antagonist DuP753 in salt-loaded stroke-prone SHR. In: Current Advances in ACE Inhibition 2. Churchill Livingstone, London. 1991; 252-5.
6. Ogiku N, Sumikawa H, Minamide S, Ishida R. Influence of imidapril on abnormal biochemical parameters in salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP). Jpn. J. Pharmacol. 1993; 61: 69-73.
7. Ogiku N, Sumikawa H, Hashimoto Y, Ishida R. Prophylactic effect of imidapril on stroke on stroke-prone spontaneously hypertensive rats. Stroke 1993; 24: 245-52.
8. Fornes P, Richer C, Vacher E, Bruneval P, Giudicelli JF. Losartan's protective rats persist durably after treatment withdrawal. J. Cardiovasc. Pharmacol. 1993; 22: 305-13.
9. Brown JJ, Davies DL, Lever AF, Robertson JIS. Influence of sodium loading and sodium depletion on plasma-renin in man. Lancet 1963; i: 278-9.
10. Iwao H, Michelakis AM. Effect of sodium intake on biosynthesis of renin. Jpn. Circ. J. 1982; 46: 506-11.
11. Kawano K, Yasuda S, Fujishima K, Nagura J, Hachisu M, Konno F. In vitro profile of ME3221, a novel nonpeptide angiotensin II (AII) receptor antagonist. Jpn. J. Pharmacol. 1994; 64 (Suppl. 1): 331P.
12. Nagura J, Fujishima K, Kawano K, Yasuda S, Hachisu M, Konno F. Pharmacological profile of ME3221, a novel angiotensin II (AII) receptor antagonist. J. Hyp. 1994; 12 (Suppl. 3): S99.
13. Nagura J, Yasuda S, Fujishima K et al. Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist. Eur J. Pharmacol. 1995; 274: 201-11.
14. Yasuda S, Chen H, Fujishima K et al. In vivo pharmacological profile of ME3221, a novel angiotensin II(AII) receptor antagonist. Jpn. J. Pharmacol. 1994; 64 (Suppl. I): 331P.
15. Nagura J, Chen H, Yamamoto M et al. Effects of chronic treatment with ME3221 on blood pressure and mortality in aged stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 1994; Suppl. 1: S74.
16. 1 receptor antagonist. J. Pharmacol. Exp. Ther. 1991; 259: 861-70.
17. Wong PC, Price WA, Chiu AT et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 1990; 255: 211-17.
18. Bagdon WJ, Bokelman DL, Stone CA, Usui T. Toxicity study of MK-421 (Enalapril maleate)(II) Subacute, chronic toxicity studies, saline supplementation, sodium-depletion studies in rats. (Summary in English). Jpn. Pharmacol. Ther. 1985; 13: 425-66.
19. Aoki K, Yamori Y, Ooshima A, Okamoto K. Effects of high or low sodium intake in spontaneously hypertensive rats. Jpn. Circ. J. 1972; 36: 539-45.
20. Blantz RC, Konnen KS, Tucker BJ. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J. Clin. Invest. 1976; 57: 419-34.
21. Thomas GR, Walder CE, Thiemermann C, Vane JR. Regional vascular resistance and haemodynamics in the spontaneously hypertensive rat: The effects of bradykinin. J. Cardiovasc. Pharmacol. 1990; 15: 211-17.
22. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J. Hyp. 1984; 2: 277-84.
23. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: Humans versus rodents. Jpn. J. Pharmacol. 1993; 62: 207-10.
24. Logan AG, Valasquez MT, Cohen JN. Renal cortical blood flow, cortical fraction and cortical blood volume in hypertensive patients. Circulation 1973; 47: 1306-12.
25. Nagaoka A. Pharmacological prevention of cerebral stroke in stroke-prone spontaneously hypertensive rats. J. Hyp. 1986; 4 (Suppl. 3): S523-5.
26. Wienen W, Mauz BM, Van Meel JCA, Entzeroth M. Different type of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. Molec. Pharmacol. 1992; 41: 1081-8.
27. Christ D, Kilkson T, Wong N, Lam G. Formation and disposition of EXP3174, a pharmacologically active metabolite of the novel angiotensin II receptor antagonist DuP753. Third North American ISSX Meeting, San Diego. 1990; 34: 21 (Abstract).
28. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br. J. Clin. Pharmacol. 1993; 35: 290-7.
29. Shibota M, Nagaoka A, Shino A, Fujita T. Renin-angiotensin system in stroke-prone spontaneously hypertensive rats. Am. J. Physiol. 1979; 236: H409-16.
30. Kotchen TA, Galla JH, Luke RG. Contribution of chloride to the inhibition of plasma renin by sodium chloride in the rat. Kidney Int. 1978; 13: 201-7.
31. Matsunaga M, Yamamoto J, Hara A, Yamori Y, Ogino K, Okamoto K. Plasma renin and hypertensive vascular complications: An observation in the stroke-prone spontaneously hypertensive rats. Jpn. Circ. J. 1975; 39: 1305-11.
32. Derkx FHM, Tan-Tjiong L, Wenting GJ, Boomsma F, Man In't Veld AJ, Schalekamp MADH. Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. Hypertension 1983; 5: 244-56.
33. Chan DP, Sandok EK, Aarhus LL, Heublein DM, Burnett JC Jr. Renal specific actions of angiotensin II receptor antagonism in the anesthetized dog. Am. J. Hyp. 1992; 5: 354-60.